With Ohio's gubernatorial contest on November 3rd approaching, Democratic contender Dr. Amy Acton has directed pointed criticism at Republican rival Vivek Ramaswamy over his involvement in the development and promotion of an Alzheimer's drug that ultimately did not succeed.
A campaign advertisement for Acton that received broad airplay across Ohio television included Norman Wernet III, a Bexley resident, who stated in the footage that Ramaswamy had promoted an Alzheimer's treatment the candidate allegedly knew to be ineffective, causing harm to families such as his own. One source described Ramaswamy as having built a fortune by defrauding ordinary people.
On the business side, Ramaswamy established the biopharmaceutical firm Roivant Sciences and later set up a subsidiary called Axovant Sciences, which acquired the drug intepirdine through a $5 million purchase from GlaxoSmithKline that closed in December 2014. Researchers were examining intepirdine as a possible Alzheimer's therapy, with the compound intended for use alongside an existing medication.
Data gathered through GSK's clinical programme showed the tablet — a compound intended to elevate a brain chemical involved in memory formation and retention — fell short of the required efficacy threshold. Four Phase 2 trials involving patients with mild-to-moderate Alzheimer's disease had already been run by GSK on intepirdine before Axovant's acquisition of the compound.
Among the 371 participants enrolled in one trial, those receiving elevated dosages showed broader gains in day-to-day functioning, though the data did not yield statistically reliable evidence of improvement in cognitive measures. Among 198 trial participants in another arm, the compound showed measurable benefit whether administered on its own or alongside donepezil, a prescribed agent commonly given to people managing memory decline linked to dementia or Alzheimer's disease.
Between 2008 and 2010, two larger-scale trials enrolled a combined 1,260 patients and arrived at mixed conclusions: a 576-patient arm testing intepirdine as a standalone therapy detected no improvement over placebo that reached statistical thresholds, while a separate 684-patient arm — in which all participants were already receiving donepezil — yielded statistically measurable gains on certain outcome measures yet still fell short of what would constitute an overall passing result. Pooled findings from all four GSK trials pointed to modest potential when intepirdine was paired with donepezil, yet neither trial arm demonstrated that the drug delivered measurable benefit on a standalone basis.
Ahead of Axovant's 2015 stock market listing — at a time when the company carried a valuation in the vicinity of $3 billion — Ramaswamy appeared before cameras and microphones on a number of occasions to discuss intepirdine. In a television interview, he put forward the position that the compound had a reasonable prospect of gaining regulatory approval and that, should it do so, patients living with the condition stood to see measurable improvements in both their cognitive abilities and their capacity to manage everyday tasks, based on the evidence then available.
What Ramaswamy's remarks left unaddressed was that a portion of the more favourable trial outcomes were drawn from patients receiving intepirdine alongside donepezil, rather than from those taking intepirdine on its own. During that same interview, Ramaswamy also described the drug as outperforming the placebo by a margin he characterised as statistically meaningful — though his campaign did not identify which study underpinned that claim when contacted for clarification.
Findings from GSK's foundational studies conducted in 2008 and 2010 were taken up for fresh examination in a paper that Geetha Ramaswamy and fellow researchers published in July 2015. The researchers' findings, published in Alzheimer's & Dementia — the journal of the Alzheimer's Association — described intepirdine as well-tolerated and as having improved both cognition and function when used alongside donepezil, with the authors calling for additional trials to build on those results.
Kathy Liu, whose research at University College London centres on agitation and tailored therapies for Alzheimer's disease, noted in broadcast remarks that abstracts presented at conferences typically carry less detail than fully peer-reviewed publications, and that data from such presentations alone rarely constitutes the kind of evidence needed to establish whether a treatment is effective.
Regulatory disclosures lodged with the U.S. Securities and Exchange Commission place Ramaswamy in a dual capacity at Axovant — as its principal executive officer and as a board member — with both roles taking effect from March 2015. Regulatory disclosures filed with the SEC detail equity-based pay of $36.7 million awarded to Ramaswamy during the 2016 fiscal year, alongside an additional $41,312 that same year and $1 million from the prior fiscal year, both flowing through a Roivant compensation arrangement.
His direct personal stake in the company amounted to under 1%, while the bulk of his financial exposure to Axovant ran through the shareholding held by Roivant. The public records do not indicate whether those shares were later converted to cash, or how much of his total compensation tied to Axovant and Roivant can be traced back specifically to intepirdine.
When Axovant's Phase 3 trial concluded — enrolling upwards of 1,300 people living with dementia — the data showed intepirdine performed no better than a placebo, with the company already listed on public markets by that point. Share value for the firm went into a sustained decline from which it did not rebound. Operations at Axovant came to an end when the company wound down in 2023.
Speaking afterward with an interviewer, Ramaswamy said the drug's failure left him with a degree of personal unease.
Dr. David P. Weber — an accounting scholar at West Virginia University whose earlier career included work as a chief investigator at the SEC — noted that labelling Ramaswamy's promotion of intepirdine a "scam" or "pump and dump" stretches beyond what the available evidence can actually bear, even as Roivant's stated mission centred on steering drugs toward approval and a profitable exit remained an accessible outcome for both the company and its employees. No criminal charges have been filed against Ramaswamy, and Weber pointed out that a failed investment does not constitute fraud, adding that Alzheimer's drug development has long carried one of the highest rates of failure in the pharmaceutical industry.
Pointing to the company's willingness to fund a costly Phase 3 trial, Weber argued that such an investment runs counter to the notion that its promoters anticipated the drug's failure, and noted that an unsuccessful clinical trial does not, by itself, amount to proof of fraud.
